Figure 5. A selective FoxO1 inhibitor, AS1842856, attenuates eosinophilic lung inflammation in sensitized WT mice that is challenged with the DRA allergens.

A. WT mice were subjected to DRA sensitization and challenge as shown in the protocol depicted in Figure 3B. Prior to allergen challenge, mice were treated with vehicle or 20mg/kg of AS1842856, a selective FoxO1 inhibitor. B. As shown, eosinophilic inflammation was attenuated in WT mice by pharmacologic inhibition of FoxO1. C. Total cells and macrophages/eosinophils influx in BAL fluid were counted based on total amount of BAL cells, analyzed by flow cytometry. D. This was confirmed by histology as shown. E. PAS-stained lung sections from the mice exposed to PBS or DRA. Black arrowheads indicate PAS-positive goblet cells. Data are representative of at least three independent experiments (A-E). (N = 6-8) *p < 0.05 and **p < 0.01 vs. DRA.